announced today that it offers gained a $6 million milestone payment from Bristol-Myers Squibb Firm related to the acceptance of preliminary regulatory filings to begin with Phase 1 clinical research for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense medication that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to recognize antisense medications targeting PCSK9 to lower low-density lipoprotein cholesterol. ‘We are happy with the success of our partnership with Bristol-Myers Squibb, and our ability to deliver a drug candidate within the 1st yr of the collaboration.Dr. Rodney Baker, medical director of the division of crisis medication at Nicklaus Children’s Medical center in Miami, stated, ‘I’ve seen the amounts decrease over the last many years.’ Baker thinks whatever pediatricians are doing to warn parents to keep medicines out of kids’ hands is working. Tamper-proof packaging may be helping keep kids from engaging in medications also, Baker said. ‘Unsupervised medicine exposures are preventable,’ Lovegrove said. ‘Curious small children can take action quickly, but carrying out a few simple actions every time medicines are used might help decrease the chance of a child getting into medicines and ending up in the emergency room,’ she said. Lovegrove said parents and other caregivers may: Keep all drugs in a safe area that is too high for young children to attain or see.